Abeona Therapeutics (ABEO) Cash from Financing Activities (2012 - 2026)

Abeona Therapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 132.83% year-over-year to -$2.2 million in Q1 2026; TTM through Mar 2026 was $17.0 million, a 80.05% decrease from a year earlier, with the FY2025 full-year figure at $26.0 million, down 74.99% from the prior year.
• Cash from Financing Activities retreated to -$2.2 million in Q1 2026 per ABEO's latest filing, from $3.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $73.7 million in Q2 2024 and bottomed at -$2.2 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is $6.6 million (2023), against an average of $14.1 million.
• Across the five-year window, Cash from Financing Activities jumped 636100.0% in 2024 and sank 132.83% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $42.8 million in 2022, then sank by 82.54% to $7.5 million in 2023, then retreated by 28.83% to $5.3 million in 2024, then sank by 31.99% to $3.6 million in 2025, then sank by 161.48% to -$2.2 million in 2026.
• Per Business Quant, the three latest ABEO Cash from Financing Activities figures stand at -$2.2 million (Q1 2026), $3.6 million (Q4 2025), and $5.2 million (Q3 2025).